Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial

JH Butt, P Dewan, B Merkely, J Belohlávek… - Annals of internal …, 2022 - acpjournals.org
Background: Frailty may modify the risk− benefit profile of certain treatments, and frail
patients may have reduced tolerance to treatments. Objective: To investigate the efficacy of …
被引用次数：92 相关文章

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial

JH Butt, P Dewan, B Merkely… - Annals of Internal …, 2022 - publicum.umed.lodz.pl
Background: Frailty may modify the risk-benefit profile of certain treatments, and frail patients
may have reduced tolerance to treatments. Objective: To investigate the efficacy of …

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial.

JH Butt, P Dewan, B Merkely, J Belohlávek… - Annals of Internal …, 2022 - europepmc.org
Background Frailty may modify the risk-benefit profile of certain treatments, and frail patients
may have reduced tolerance to treatments. Objective To investigate the efficacy of …

Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction

JH Butt, P Dewan, B Merkely, J Belohlávek… - Annals of Internal …, 2022 - eprints.gla.ac.uk
Background: Frailty may modify the risk− benefit profile of certain treatments, and frail
patients may have reduced tolerance to treatments. Objective: To investigate the efficacy of …

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial

JH Butt, P Dewan, B Merkely… - Annals of internal …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Frailty may modify the risk-benefit profile of certain treatments, and frail patients
may have reduced tolerance to treatments. Objective To investigate the efficacy of …

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial.

JH Butt, P Dewan, B Merkely, J Belohlavek… - Annals of internal …, 2022 - diva-portal.org
BACKGROUND: Frailty may modify the risk-benefit profile of certain treatments, and frail
patients may have reduced tolerance to treatments. OBJECTIVE: To investigate the efficacy …

[引用][C] Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction

JH Butt, P Dewan, B Merkely, J Belohlávek… - Annals of Internal …, 2022 - cir.nii.ac.jp
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection
Fraction | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

[引用][C] Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial

JH Butt, P Dewan, KF Docherty, PS Jhund… - Annals of Internal …, 2022 - elibrary.ru

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial

JH Butt, P Dewan, B Merkely… - Annals of Internal …, 2022 - research.regionh.dk
BACKGROUND: Frailty may modify the risk-benefit profile of certain treatments, and frail
patients may have reduced tolerance to treatments. OBJECTIVE: To investigate the efficacy …

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial

JH Butt, P Dewan, B Merkely… - Annals of Internal …, 2022 - publicum.umed.lodz.pl
Background: Frailty may modify the risk-benefit profile of certain treatments, and frail patients
may have reduced tolerance to treatments. Objective: To investigate the efficacy of …